Bartsch, R; Harbeck, N; Wrobel, D; Zaiss, M; Terhaag, J; Guth, D; Distelrath, A; Wuerstlein, R; Zahn, MO; Luftner, D; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Gorray, M; Breitenstein, U.
Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib
BREAST. 2023; 68: S20-S21.
[Poster]
Web of Science